cannabidiol transdermal gel (BTX1503) / Botanix Pharma - LARVOL DELTA

Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris (clinicaltrials.gov) - P2; N=368; Completed; Sponsor: Botanix Pharmaceuticals; Active, not recruiting ➔ Completed

Clinical • Trial completion

Why the Botanix share price is sagging today (The Motley Fool) - "Botanix’s BTX 1503 Phase 2 acne and BTX 1204 Phase 2 atopic dermatitis studies remain on track for completion...During the quarter, Botanix had net cash outflows of A$4.6m with $4.3m invested in R&D activities, primarily to progress the two Phase 2 clinical studies (BTX 1503 and BTX 1204). At the end of the quarter, Botanix held $4.7m in cash. Forecast cash outflows for R&D activities is estimated to be $5.7m for the upcoming quarter."

Commercial • Trial status